LT4225B - Immuno-stimulatory monoclonal antibodies - Google Patents

Immuno-stimulatory monoclonal antibodies Download PDF

Info

Publication number
LT4225B
LT4225B LT96-115A LT96115A LT4225B LT 4225 B LT4225 B LT 4225B LT 96115 A LT96115 A LT 96115A LT 4225 B LT4225 B LT 4225B
Authority
LT
Lithuania
Prior art keywords
bat
cells
mak
monoclonal antibody
cell line
Prior art date
Application number
LT96-115A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT96115A (en
Inventor
Britta Hardy
Avraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of LT96115A publication Critical patent/LT96115A/xx
Publication of LT4225B publication Critical patent/LT4225B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
LT96-115A 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies LT4225B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
LT96115A LT96115A (en) 1997-05-26
LT4225B true LT4225B (en) 1997-10-27

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
LT96-115A LT4225B (en) 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004L (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DK1673397T3 (da) * 2003-07-02 2011-03-07 Univ Genova Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR101562580B1 (ko) * 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
ES2639857T3 (es) * 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
B. HARDY ET AL.: "A monoclonal antibody to human B lyphoblastoid cells activates human and murine T lymphocytes", CELL IMMUNOL., 1989, pages 22 - 29
E. A. CLARK, J.A. LEDBETTER: "Amplification of the immune response by agonistic antibodies", IMMUNOL. TODAY., 1986, pages 267 - 270, XP023943599, DOI: doi:10.1016/0167-5699(86)90008-3
G. JUNG ET AL.: "Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3", J IMMUNOL., 1987, pages 639 - 644
GLASSY MC, SURH CD: "Immunodetection of cell-bound antigens using both mouse and human monoclonal antibodies", J IMMUNOL METHODS, 1985, pages 115, XP023992301, DOI: doi:10.1016/0022-1759(85)90127-9
J. D. ELLENHORN ET AL.: "In vivo administration of an anti-CD3 prevents malignant progressor tumor growth", SCIENCE, 1988, pages 569 - 571, XP001084126, DOI: doi:10.1126/science.2902689
JAMIESON G. A. ET AL.: "Isolation and characterization of plasma membranes and intact nuclei from lymphoid cells", J. BIOL. CHEM., 1977, pages 2137
KÖHLER G, MILSTEIN C.: "Continuous cultures of fused cells secreting antibody of predefined specificity", NATURE, 1975, pages 495, XP002024548
M. K. JENKINS ET AL.: "CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells", J IMMUNOL., 1991, pages 2461 - 2466
MORETTA ET AL.: "CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta", J EXP MED., 1991, pages 1393 - 1398, XP055219293, DOI: doi:10.1084/jem.174.6.1393
R. A. VAN LIER ET AL.: "Signals involved in T-cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies", EUR. J. IMMUNOL., 1988, pages 167 - 172
R. VAN LIER ET AL.: "Studies on monocyte dependence on T-cell proliferation induced by monoclonal antibodies directed against region I and II of CD2 antigen", IMMUNOLOGY, 1989, pages 333 - 338
S. C. MEUER ET AL.: "Triggering of the T3-T1 antigen-receptor complex results in clonal T cell proliferation through an interleukin-2 dependent autocrine pathway", PROC. NATL. ACAD. SCI. USA, 1984, pages 1509 - 1513
S. E. TOWNSEND, J. P ALLISON: "Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells", SCIENCE, 1993, pages 368 - 370, XP000943266, DOI: doi:10.1126/science.7678351
S. GALLINGER ET AL.: "Comparison of cellular immunotherapies and anti-CD3 inthe treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice", CANCER RES., 1990, pages 2476 - 2480
VAN WAUVE J. P. ET AL.: "OKT3: a monoclonal anti-human T lymphocyte antibody and potent mitogenic properties", J IMMUNOL., 1980, pages 2708 - 2713

Also Published As

Publication number Publication date
MD1374F2 (ro) 1999-12-31
NO963168D0 (no) 1996-07-29
FI963004A7 (fi) 1996-09-27
LT96115A (en) 1997-05-26
DE69504955D1 (de) 1998-10-29
NO963168L (no) 1996-09-27
RU2155190C2 (ru) 2000-08-27
NO317020B1 (no) 2004-07-26
WO1995020605A1 (en) 1995-08-03
ATE171461T1 (de) 1998-10-15
CN1145077A (zh) 1997-03-12
LV11624B (en) 1997-06-20
MX9603080A (es) 1998-01-31
LV11624A (en) 1996-12-20
IL108501A (en) 1998-10-30
MD1374G2 (ro) 2000-09-30
CA2182289C (en) 2003-10-21
JPH09508390A (ja) 1997-08-26
CA2182289A1 (en) 1995-08-03
JP3478398B2 (ja) 2003-12-15
AU693526B2 (en) 1998-07-02
EP0742795A1 (en) 1996-11-20
US5897862A (en) 1999-04-27
AU1868695A (en) 1995-08-15
FI963004L (fi) 1996-09-27
DE69504955T2 (de) 1999-05-27
EE03285B1 (et) 2000-08-15
CN1052733C (zh) 2000-05-24
FI963004A0 (fi) 1996-07-29
DK0742795T3 (da) 1999-06-14
ES2124533T3 (es) 1999-02-01
IL108501A0 (en) 1994-05-30
EP0742795B1 (en) 1998-09-23

Similar Documents

Publication Publication Date Title
LT4225B (en) Immuno-stimulatory monoclonal antibodies
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
EP2992020B1 (en) Cs1-specific chimeric antigen receptor engineered immune effector cells
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
JPH0198477A (ja) ＩｇＧモノクローナル抗体−生産性ハイブリドマ
CN111699001A (zh) 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节
KR20200030337A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
Cerutti et al. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity
AU2022260700A9 (en) Chimeric antigen receptor (car)-t cells
Hardy et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice
Kroesen et al. Reduction of EGP‐2‐positive pulmonary metastases by bispecific‐antibody‐redirected T cells in an immunocompetent rat model
JPH01126558A (ja) 抗体依存性細胞性細胞毒性の測定方法
AU2022262282A1 (en) Chimeric antigen receptor (car)-t cells
Wang et al. Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
US20240207313A1 (en) Chimeric antigen receptor (car)-t cells
US20220106402A1 (en) Antibody
KR20230085116A (ko) 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
Graham The functional characterisation of the C-type lectin: Clecsf8
HK1218925B (en) Cs1-specific chimeric antigen receptor engineered immune effector cells

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20010130